Author: PharmaSignal News Desk

Pfizer Metsera deal finalizes at $10 billion, enhancing Pfizer’s pipeline and market position.

Ozempic pricing is under scrutiny as Senator Sanders suggests generic versions could cost under $100/month.

Strand Therapeutics promotes Prashant Nambiar to Chief Scientific Officer, enhancing leadership with his prior experience as Senior Vice President.

Zymeworks royalty-driven model aims to create consistent shareholder value following promising cancer drug data.

Merck Winrevair heart study demonstrates significant improvement in blood flow for heart failure patients.

Alkermes bidding war with Lundbeck over a sleepiness drug could impact its market strategy and financial outlook.

AstraZeneca Virginia investment enhances ADC production capabilities with a $500 million boost.

AmgenNow platform enhances direct-to-consumer access, aiming to streamline patient engagement and improve market reach.

Novo Nordisk acquires Akero Therapeutics for $5.2 billion, enhancing its MASH treatment pipeline.

Colorado Enbrel payment limit set at $600 per unit, impacting Amgen’s pricing strategy and potentially influencing other states.